UNSPSC 51203501: Ciamexon

This classification denotes a biological response modifier with the molecular formula C11H13N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 325PG708LF, chemically known as 2-aziridinecarbonitrile, 1-((2-methoxy-6-methyl-3-pyridinyl)methyl)- but more generally known as ciamexon, which bears US NIH Compound Identifier 71759. European Medicines Agency schedules Ciamexon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06224MIG.

UNSPSC 51203501 Ciamexon is a Commodity code under which state and local governments procure pharmaceutical products, specifically antibiotic and emergency-response medications distributed through health departments and county health systems. Recent solicitations show state and local buyers acquiring specific pharmaceutical inventory — including antibiotics such as Doxycycline Hyclate and Ciprofloxacin Hydrochloride, as well as naloxone for opioid-overdose response — through both piggyback contracts leveraging statewide consortiums and direct competitive bidding. The issuing bodies include state health departments and county health authorities operating community health programs and emergency-response initiatives.

Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical warehouse contract to Chartwell Rx LLC through the MMCAP Infuse consortium on August 28, 2026 for a 12-month initial term with two renewal options, supplying Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg in bulk quantities selected as the lowest responsive bid under an Invitation for Bid process. Seminole County, Florida posted an IFB on June 30, 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to its Community Health Building in Sanford, including vendor responsibility for all shipping costs and a two-year initial term with one-year renewal option. Both opportunities reflect state and county demand for pharmaceutical supply chain management through established competitive procurement vehicles, with no explicit set-asides or enterprise program designations identified in recent awards.